je.st
news
Tag: regimen
Merck Announces Phase 3 Study of Single-Dose EMEND (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
2015-06-29 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Mercks substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). Language: English Contact: MerckMedia:Doris Li, 908-740-1903orAn Phan, 908-255-6325orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
2015-05-07 14:30:00| Merck.com - Product News
Dateline City: BERKELEY, Calif., and KENILWORTH, N.J. Study will Evaluate Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), in Combination with Plexxikons PLX3397 BERKELEY, Calif., and KENILWORTH, N.J. May 7, 2015 Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikons investigational CSF-1R inhibitor, and KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression. Language: English read more
Tags: study
combination
evaluating
collaborate
Galderma Launches First OTC Acne Regimen
2015-01-05 06:00:00| Happi Breaking News
Benzac line is formulated with pharma grade East Indian sandalwood oil.
Tags: launches
otc
acne
regimen
Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen
2014-08-26 16:20:33| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Agreement to Combine Mercks Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizers crizotinib (XALKORI) in Clinical Trial WHITEHOUSE STATION, N.J. Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizers crizotinib (XALKORI) with Mercks investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC). Language: English read more
Tags: study
combination
evaluating
collaborate
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS (raltegravir)
2014-06-05 23:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. ONCEMRK Study Globally Enrolling Treatment-Nave Adults with HIV-1 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the companys global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-nave HIV-1-infected adults. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more